Navigation Links
Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
Date:2/27/2008

(85,046) (17,476)

Litigation settlements, net (1,984) (46,154)

Integration and other non-

recurring expenses (3) 56,142 -

Tax effect of the above items (57,412) 18,761

Adjusted net earnings available to

common shareholders and adjusted

diluted cash EPS $238,265 $0.92 $253,732 $1.18

(1) The three months ended December 31, 2007 include amortization expense

related to purchased intangible assets as well as amortization of the

inventory step-up related to Merck Generics. The nine months ended

December 31, 2007 include amortization expense related to purchased

intangible assets and amortization of the inventory step-up related to

both Merck Generics and Matrix.

(2) The three and nine months ended December 31, 2007 include the premium

related to a tender offer made to holders of the Company's previously

outstanding Senior Notes, the write-off of deferred finance fees and

non-recurring financing fees and expenses related to the Company's

previously outstanding Interim Term Loan.

(3) The three and nine months ended December 31, 2007 principally include

non-recurring expenses related to the acquisition and integration of

Merck Generics (e.g., non-recurring professional and consulting fees,

retention and other non-recurring expenses).

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements", including with regard to the Company's future growth expectations, its strategic initiatives including with regard to its Dey business and Matrix's Docpharma business, the Company's synergy targets, the impact of the Perforomist(TM) launch on future EPS expectations, its planned rationalizations and optimizations of its businesses, a
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
2. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
3. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
4. Mylan Restores Availability of Generic Levothyroxine in Florida
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
8. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
9. Mylan Sets Date of 2008 Annual Meeting
10. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
11. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... patients is in early period , , TUESDAY, Feb. 5 (HealthDay ... after heart patients stop taking the clot-preventing drug Plavix are ... make this observation," said Dr. P. Michael Ho, a cardiologist ... a report in the Feb. 6 issue of the ...
... ,PLAY SAFE IN THE SUN, ... ... a,subsidiary of the L,Oreal Group, announced that they have granted the,Women,s Dermatologic ... Safe in the Sun campaign, effective April,2008. The WDS educational outreach campaign ...
... William F. Balistreri, MD, Editor of The Journal of ... the Study of Liver Diseases (AASLD) 2007 Distinguished Service ... AASLD as well as to the liver disease community. ... award. , The AASLD was privileged to honor Dr. ...
... of the sardine fishery off California for decades has ... large fluctuations in the sardine population. Before its collapse, ... and formed the setting of John Steinbecks Cannery Row ... Oceanography at UC San Diego have now shed light ...
... Magazine,s list ranks 33, COLUMBUS, Ga., Feb. ... education and leadership programs helped Aflac leap to,Number ... for,employees according to Training Magazine,s annual Top 125 ... Georgia World Congress Center, the,insurer was honored for ...
... NewYork-Presbyterian Hospital/Weill Cornell Medical Center has created an ... and treatment of the disease. The new Cancer ... Andrew Dannenberg. , A joint initiative of Weill ... will create strengthened and expanded research programs and ...
Cached Medicine News:Health News:First 90 Days After Stopping Plavix Most Dangerous 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 3Health News:William F. Balistreri, M.D., honored with Distinguished Service Award by AASLD 2Health News:Scripps scientists peg wind as the force behind fish booms and busts 2Health News:Scripps scientists peg wind as the force behind fish booms and busts 3Health News:Training Magazine Applauds Aflac's Employee Learning Programs 2Health News:Training Magazine Applauds Aflac's Employee Learning Programs 3Health News:NewYork-Presbyterian/Weill Cornell creates world-class cancer center 2
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ... Pharmaceutical Industries Ltd (NYSE: TEVA ) and ...
(Date:1/15/2014)... -- Tegra Medical is very pleased to announce the ... its new Chief Executive Officer.  Mark was promoted from ... he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in ... and manufacturing experience in medical device businesses, both in ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health ... Center by the Medical Fitness Association, a non-profit ... to achieve their full potential. The Cadence Fitness ... center in the western suburbs and second in ... the Cadence Fitness & Health Center meets guidelines ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cochlear, the global leader in implantable hearing ... Clark Cochlear Scholarship. Presented by Cochlear Americas, the Graeme ... seniors who,ve demonstrated exceptional achievements both in the classroom ... implant and will receive financial assistance toward their chosen ...
... PHILADELPHIA , May 4 ... SHPGY ), the global specialty biopharmaceutical company, today announced ... a change to the prescribing information for its once-daily ... ® (lisdexamfetamine dimesylate) Capsules CII, to include supplemental ...
Cached Medicine Technology:Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 2Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 3Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 2FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 3FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 5FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 6FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 7FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: